Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology’s antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.

Pyxis Oncology entered into definitive securities purchase agreements on June 30, 2026 for a private placement of 19,600,153 shares of common stock at $2.551 per share and accompanying warrants to buy ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

ALBANY, N.Y., Jan. 17, 2018 /PRNewswire/ -- The Board of Directors of Pyxis announces the formal launch of this United States-based not-for-profit professional association that will bring IT industry ...